Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J Says It's Wait And See On COVID-19 Vaccine Delay, Outlines Rosier Outlook for 2021

Executive Summary

It will be several days at least before more information is available about the unexpected illness in J&J's Phase III COVID-19 vaccine trial, the firm said during its third quarter financial call.

You may also be interested in...



Real-World Data, AI Play Key Roles In COVID-19 Vaccine Programs

RWD has helped with development of multiple SARS-CoV-2 vaccines already and could be a useful tool for the future, as panelists discussed at the AI Cures conference.

Quick Listen: Scrip’s Five Must-Know Things

Join us for a brief audio roundup of the major developments in the international biopharma industry over the past week, as covered by Scrip's global team.

J&J Bounces Back In Q3, Led By Interventional Devices

Johnson & Johnson’s worldwide medical device revenues grew about 50% sequentially in the third quarter to $6.2bn.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC143125

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel